Press Releases
Basal Cell Carcinoma CSR Highlights Excerpt from the Press Release: TAIPEI and SAN DIEGO, April 2, 2025 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that the completion of Clinical Study Report (CSR) for Phase 1/Dose Expansion Trial…
Read More
The Independent Data Monitoring Committee (IDMC) has recommended to continue study as planned as there are no safety concerns seen in the data reviewed Interim results demonstrate GRI-0621 to be safe and well-tolerated in the first 12 patients evaluated Interim biomarker data on track for Q2 2025 and topline results expected Q3 2025 Currently available…
Read More
A global collaboration agreement has been signed for the development and commercialization of a Granzyme B-targeted Positron Emission Tomography (PET) imaging radiotracer. This radiotracer has the potential to support the monitoring of patient immune response and supports the accelerated development for CytoSite. CytoSite will lead initial clinical development with Lantheus having an exclusive option to…
Read More
Excerpt from the Press Release: NEEDHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced final survival data from a phase 2a clinical trial of CAN-2409 in patients with stage…
Read More
Excerpt from the Press Release: BOSTON and LAUSANNE, Switzerland, March 27, 2025 /PRNewswire/ — Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces that the first patient has been dosed in its Phase IIa trial of ALY-101 in patients suffering from Alopecia Areata (AA), a chronic autoimmune disease with significant unmet medical need that…
Read More
SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, due to the potential for immune mechanism synergies and enhancement of progression-free survival (PFS) The Safety Review Committee found no unexpected toxicities in early dosing of SON-1010…
Read More
Excerpt from the Press Release: SAN DIEGO, March 25, 2025 — Sugar coatings aren’t only for candies; they also help viruses, like the ones that cause COVID-19, hide from their hosts’ immune system. Now, researchers have developed a universal vaccine that targets coronaviruses and the sugars that they use as cover. As demonstrated in animal…
Read More
Excerpt from the Press Release: The last time a new class of antibiotics reached the market was nearly three decades ago — but that could soon change, thanks to a discovery by researchers at McMaster University. A team led by renowned researcher Gerry Wright has identified a strong candidate to challenge even some of the…
Read More
Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that additional data from the Company’s Phase 1/1b clinical trial of soquelitinib for the…
Read More
Excerpt from the Press Release: BOSTON, March 13, 2025 /PRNewswire/ — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase I clinical trial has unanimously approved opening of the fourth cohort of patients based on…
Read More